Evidence
November 22, 2024Clinical Outcomes Infographic
This interactive infographic highlights the clinical and economic value of CGM in the management of type 1 and type 2 diabetes (T1D and T2D) regardless of treatment regimen. The studies featured have been published in peer-reviewed journals and presented at the 84th American Diabetes Association (ADA) Scientific Sessions. Key areas of focus pertinent to payer professionals include long-term glycemic control in T2D, HbA1c reduction in managed care, improved T2D outcomes in the community setting, cost-effectiveness in T2D, and reduced hospitalizations in T2D. Collectively, this evidence demonstrates that appropriate coverage and utilization of CGM can improve clinical outcomes and reduce diabetes-related healthcare resource utilization. Summarizing the findings in a useful format, the infographic offers key takeaways for managed care and payer professionals associated with each individual study featured.
Learn More
Real-World Managed Care Data Show Reduction in HbA1c and Diabetes-Related Resource Utilization Associated with CGM Regardless of Insulin Treatment
November 20, 2024Clinical Outcomes Article / Publication
A retrospective observational study using Aetna administrative claims data showed that CGM use was associated with clinically meaningful improvements in A1c and reduced health care resource utilization. The study, published in the Journal of Managed Care and Specialty Pharmacy, looked at a cohort of fully insured commercial and Medicare Advantage beneficiaries with diabetes and coverage for medical and pharmacy benefits. Data from 7,336 patients (74% T2D, mean age 57 years, 42% Medicare-insured, 54% male, 56% White) showed a significant improvement in A1c after CGM initiation (-0.7%, P<0.0001), including a -0.9% change in the T2D not on insulin group (n = 264). For the overall cohort, the number of patients with diabetes-related hospitalizations and emergency department visits decreased significantly by 67% and 40%, respectively (P<0.0001 for both). This real-world analysis suggests a potential for population-level clinical and economic benefits with CGM in a managed care setting, particularly among patients not using insulin.
Learn MoreOctober 7, 2024CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
Large, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
September 17, 2024Clinical Outcomes Article / Publication
A retrospective claims analysis of 74,679 adults with T2D showed significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations, and acute diabetes-related emergency room visits associated with CGM use. These sizeable reductions in health care resource utilization were observed in patients treated with non-insulin therapy (NIT; -10.1%, -31.0%, -30.7%), basal insulin therapy (BIT; -13.9%, -47.6%, -28.2%), and prandial insulin therapy (PIT; -22.6%, -52.7%, -36.6%, respectively) across the 6 to 12 month post-index period. Mean HbA1c was likewise reduced across all treatment types at approximately 3 months and sustained throughout the post-index period (NIT, -1.1%; BIT, -1.1%; and PIT, -0.9%; P< 0.0001).Study authors noted that these findings support expanded coverage of CGM use for people with T2D regardless of treatment type to improve glycemic control and reduce hospitalizations and overall health care costs. Furthermore, the study suggests that managed care and payer decision makers can benefit from consideration of CGM use in patients with T2D who are often ineligible for coverage as a means of managing the total cost of care.
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. September 12, 2024. doi: 10.1111/dom.15866. Epub ahead of print.
Learn MoreSeptember 11, 2024CGM Technology and Digital Health CE Activities
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
LEARN MOREEmerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
This interactive infographic highlights the clinical and economic value of CGM in the management of type 1 and type 2 diabetes (T1D and T2D) regardless of treatment regimen. The studies featured have been published in peer-reviewed journals and presented at the 84th American Diabetes Association (ADA) Scientific Sessions. Key areas of focus pertinent to payer professionals include long-term glycemic control in T2D, HbA1c reduction in managed care, improved T2D outcomes in the community setting, cost-effectiveness in T2D, and reduced hospitalizations in T2D. Collectively, this evidence demonstrates that appropriate coverage and utilization of CGM can improve clinical outcomes and reduce diabetes-related healthcare resource utilization. Summarizing the findings in a useful format, the infographic offers key takeaways for managed care and payer professionals associated with each individual study featured.
Learn MoreReal-World Managed Care Data Show Reduction in HbA1c and Diabetes-Related Resource Utilization Associated with CGM Regardless of Insulin Treatment
November 20, 2024Clinical Outcomes Article / Publication
A retrospective observational study using Aetna administrative claims data showed that CGM use was associated with clinically meaningful improvements in A1c and reduced health care resource utilization. The study, published in the Journal of Managed Care and Specialty Pharmacy, looked at a cohort of fully insured commercial and Medicare Advantage beneficiaries with diabetes and coverage for medical and pharmacy benefits. Data from 7,336 patients (74% T2D, mean age 57 years, 42% Medicare-insured, 54% male, 56% White) showed a significant improvement in A1c after CGM initiation (-0.7%, P<0.0001), including a -0.9% change in the T2D not on insulin group (n = 264). For the overall cohort, the number of patients with diabetes-related hospitalizations and emergency department visits decreased significantly by 67% and 40%, respectively (P<0.0001 for both). This real-world analysis suggests a potential for population-level clinical and economic benefits with CGM in a managed care setting, particularly among patients not using insulin.
Learn MoreOctober 7, 2024CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
Large, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
September 17, 2024Clinical Outcomes Article / Publication
A retrospective claims analysis of 74,679 adults with T2D showed significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations, and acute diabetes-related emergency room visits associated with CGM use. These sizeable reductions in health care resource utilization were observed in patients treated with non-insulin therapy (NIT; -10.1%, -31.0%, -30.7%), basal insulin therapy (BIT; -13.9%, -47.6%, -28.2%), and prandial insulin therapy (PIT; -22.6%, -52.7%, -36.6%, respectively) across the 6 to 12 month post-index period. Mean HbA1c was likewise reduced across all treatment types at approximately 3 months and sustained throughout the post-index period (NIT, -1.1%; BIT, -1.1%; and PIT, -0.9%; P< 0.0001).Study authors noted that these findings support expanded coverage of CGM use for people with T2D regardless of treatment type to improve glycemic control and reduce hospitalizations and overall health care costs. Furthermore, the study suggests that managed care and payer decision makers can benefit from consideration of CGM use in patients with T2D who are often ineligible for coverage as a means of managing the total cost of care.
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. September 12, 2024. doi: 10.1111/dom.15866. Epub ahead of print.
Learn MoreSeptember 11, 2024CGM Technology and Digital Health CE Activities
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
LEARN MOREEmerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Real-World Managed Care Data Show Reduction in HbA1c and Diabetes-Related Resource Utilization Associated with CGM Regardless of Insulin Treatment
A retrospective observational study using Aetna administrative claims data showed that CGM use was associated with clinically meaningful improvements in A1c and reduced health care resource utilization. The study, published in the Journal of Managed Care and Specialty Pharmacy, looked at a cohort of fully insured commercial and Medicare Advantage beneficiaries with diabetes and coverage for medical and pharmacy benefits. Data from 7,336 patients (74% T2D, mean age 57 years, 42% Medicare-insured, 54% male, 56% White) showed a significant improvement in A1c after CGM initiation (-0.7%, P<0.0001), including a -0.9% change in the T2D not on insulin group (n = 264). For the overall cohort, the number of patients with diabetes-related hospitalizations and emergency department visits decreased significantly by 67% and 40%, respectively (P<0.0001 for both). This real-world analysis suggests a potential for population-level clinical and economic benefits with CGM in a managed care setting, particularly among patients not using insulin.
Learn MoreOctober 7, 2024CGM Technology and Digital Health CE Activities
Download a comprehensive listing of continuing education programs for pharmacists, physicians and nurses on the topic of CGM.
Learn More
Large, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
September 17, 2024Clinical Outcomes Article / Publication
A retrospective claims analysis of 74,679 adults with T2D showed significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations, and acute diabetes-related emergency room visits associated with CGM use. These sizeable reductions in health care resource utilization were observed in patients treated with non-insulin therapy (NIT; -10.1%, -31.0%, -30.7%), basal insulin therapy (BIT; -13.9%, -47.6%, -28.2%), and prandial insulin therapy (PIT; -22.6%, -52.7%, -36.6%, respectively) across the 6 to 12 month post-index period. Mean HbA1c was likewise reduced across all treatment types at approximately 3 months and sustained throughout the post-index period (NIT, -1.1%; BIT, -1.1%; and PIT, -0.9%; P< 0.0001).Study authors noted that these findings support expanded coverage of CGM use for people with T2D regardless of treatment type to improve glycemic control and reduce hospitalizations and overall health care costs. Furthermore, the study suggests that managed care and payer decision makers can benefit from consideration of CGM use in patients with T2D who are often ineligible for coverage as a means of managing the total cost of care.
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. September 12, 2024. doi: 10.1111/dom.15866. Epub ahead of print.
Learn MoreSeptember 11, 2024CGM Technology and Digital Health CE Activities
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
LEARN MOREEmerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Download a comprehensive listing of continuing education programs for pharmacists, physicians and nurses on the topic of CGM.
Learn MoreLarge, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
September 17, 2024Clinical Outcomes Article / Publication
A retrospective claims analysis of 74,679 adults with T2D showed significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations, and acute diabetes-related emergency room visits associated with CGM use. These sizeable reductions in health care resource utilization were observed in patients treated with non-insulin therapy (NIT; -10.1%, -31.0%, -30.7%), basal insulin therapy (BIT; -13.9%, -47.6%, -28.2%), and prandial insulin therapy (PIT; -22.6%, -52.7%, -36.6%, respectively) across the 6 to 12 month post-index period. Mean HbA1c was likewise reduced across all treatment types at approximately 3 months and sustained throughout the post-index period (NIT, -1.1%; BIT, -1.1%; and PIT, -0.9%; P< 0.0001).Study authors noted that these findings support expanded coverage of CGM use for people with T2D regardless of treatment type to improve glycemic control and reduce hospitalizations and overall health care costs. Furthermore, the study suggests that managed care and payer decision makers can benefit from consideration of CGM use in patients with T2D who are often ineligible for coverage as a means of managing the total cost of care.
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. September 12, 2024. doi: 10.1111/dom.15866. Epub ahead of print.
Learn MoreSeptember 11, 2024CGM Technology and Digital Health CE Activities
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
LEARN MOREEmerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Large, Real-World Retrospective Study Shows Reduced Health Care Resource Utilization and Improved Glycemic Outcomes with CGM in T2D Regardless of Treatment Type
A retrospective claims analysis of 74,679 adults with T2D showed significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations, and acute diabetes-related emergency room visits associated with CGM use. These sizeable reductions in health care resource utilization were observed in patients treated with non-insulin therapy (NIT; -10.1%, -31.0%, -30.7%), basal insulin therapy (BIT; -13.9%, -47.6%, -28.2%), and prandial insulin therapy (PIT; -22.6%, -52.7%, -36.6%, respectively) across the 6 to 12 month post-index period. Mean HbA1c was likewise reduced across all treatment types at approximately 3 months and sustained throughout the post-index period (NIT, -1.1%; BIT, -1.1%; and PIT, -0.9%; P< 0.0001).Study authors noted that these findings support expanded coverage of CGM use for people with T2D regardless of treatment type to improve glycemic control and reduce hospitalizations and overall health care costs. Furthermore, the study suggests that managed care and payer decision makers can benefit from consideration of CGM use in patients with T2D who are often ineligible for coverage as a means of managing the total cost of care.
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. September 12, 2024. doi: 10.1111/dom.15866. Epub ahead of print.
Learn MoreSeptember 11, 2024CGM Technology and Digital Health CE Activities
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
LEARN MOREEmerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Program Description
Patients with diabetes who are hospitalized and have uncontrolled blood glucose levels are at a higher risk for morbidity, mortality, and health care costs. Pharmacists practicing within hospital and health-system settings can identify patients who might benefit from continuous glucose monitoring (CGM) devices. This program will outline responsibilities for health-system pharmacists to improve the integration of CGM into practice for appropriate patients. The panelists will discuss insurance coverage options, potential cost considerations, and the importance of follow-up communication with patients to address initial challenges. Panelists will share their collective experience and discuss opportunities for collaboration to ensure a smooth transition to CGM use after discharge.
Target audience: Health-system and community pharmacists
Type of activity: Application
Emerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
September 11, 2024Clinical Outcomes Video
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents
- CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Learn MoreClosing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Emerging Scientific Evidence Supports Broader Use and Benefits of CGM at the Patient and Population Level
This video reviews recent findings on the use of CGM. The studies highlight real world evidence supporting the broader use and
benefit of CGM at the patient and population level. Key takeaways include:
- The use of CGM has demonstrated clinical utility in non-intensively treated type two diabetes, including individuals using
non-insulin agents - CGM has shown an A1c reduction across diverse population who have historically experienced disparities in access to CGM
- CGM has demonstrated a clinical value in individuals also utilizing GLP1
- CGM is linked to reduced mortality in people with type one and type two diabetes using insulin
Closing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
August 28, 2024Population Health Article / Publication
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn More
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Closing Care Gaps in Diabetes Management Through Advanced Data Integration with Continuous Glucose Monitors
Clinical practice guidelines endorse the use of CGM, and CMS recently expanded coverage for this technological intervention. However, disparities due to racial/ethnic bias, insurance coverage, and healthcare literacy present barriers to equitable diabetes care and access to CGM. Data show that members of minority populations, those with lower socioeconomic status and those without private insurance are disproportionately affected by diabetes and have lower rates of CGM use. This article, published in Managed Healthcare Executive, notes that payers should place greater emphasis on expanding patient education programs. In addition, further action must be taken to inform patients and to increase adoption and dissemination of new diabetes care technology. In addition to enhancing provider knowledge of CGM and its role in optimal patient care, managed care and payer professionals are tasked with ensuring that unnecessary barriers do not exist in current coverage policies.
In an accompanying video series, Estay Greene, PharmD, MBA, provides insights on ways to improve the care of patients with diabetes from the payer persepective, with a focus on data supporting the use of CGM. Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and David Hines also share their perspectives on social determinants of health in diabetes management and overcoming disparities in care with appropriate use of CGM.
Learn MorePayer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 12, 2024CGM Technology and Digital Health CE Activities
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Payer IMPACT Brief: Diabetes Quality Management – Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
This Payer IMPACT Brief summarizes the key points of a Satellite Symposium held at the Academy of Managed Care Pharmacy 2024 Annual Meeting.
Learn MorePayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
June 3, 2024Population Health CE Activities
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Click here to begin!
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
PayerTalkCE™ Presents: Diabetes Quality Management–Trends and Opportunities for Continuous Glucose Monitoring in Managed Care Pharmacy
Intended Audience: This activity is designed to meet the education needs of managed are pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: December 31, 2025
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent updates to HEDIS measures in diabetes care, including opportunities associated with glucose management indicator (GMI) and an increased focus on equity
- Describe the synergistic impact of CGM and GLP-1 agonists
- Outline health plan best practices and strategies for streamlined coverage, access, and value of CGM
Expert Faculty
Clinical Pharmacist, Medicare Stars & Clinical Quality
Optum Rx
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc. Medical Affairs.
May 23, 2024Coverage and Benefit Design CGM Best Practices
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More
This podcast episode explores the evolving landscape of payor coverage for diabetes and continuous glucose monitoring (CGM). We delve into key trends and developments in the payor space for diabetes management, how CGM coverage and utilization management have changed, and the recipe for successful partnerships in optimizing diabetes care through CGM.
Learn More